Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab plus VRd versus VRd in transplant-ineligible newly diagnosed multiple myeloma
2017-002238-21Phase 3Active
- Sponsor
- Sanofi
- Start
- Aug 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of isatuximab in multiple myeloma (MM) (2 arms), sponsored by Sanofi. Primary endpoint: Progression-free survival. Started Aug 2017; status: active.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2017-002238-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002238-21.